Lung Cancer Symptom Assessment and Management Intervention

Dana-Farber Cancer Institute2 sites in 1 country179 target enrollmentMay 2008

ConditionsLung Cancer

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Lung Cancer
Sponsor: Dana-Farber Cancer Institute
Enrollment: 179
Locations: 2
Primary Endpoint: % completion of intervention use and adherence to suggested symptom management strategies.
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting (phase I) and its feasibility in a clinical setting in a group randomized trial (phase II).

Registry

clinicaltrials.gov

Start Date

May 2008

End Date

June 2016

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Dana-Farber Cancer Institute

Responsible Party

Principal Investigator

Mary E. Cooley, Phd

Nurse Scientist

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

•HCPs: attending physician, thoracic medical oncologist, expected to work in the setting for at least 2 years.
•Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell lung cancer OR limited or extensive stage small cell lung cancer; receiving care in the out-patient setting; receiving treatment with chemotherapy +/- additional therapies; English speaking.